Urology Field Sales Intern
About the job
- Currently enrolled in an undergraduate degree program in Business, Engineering, or another technical or relevant coursework area as a rising junior or senior.
- Have a strong record of academic achievement and leadership experiences.
- Demonstrate analytical, technical, communication, and problem-solving skills.
- Be able to build and maintain strong customer relationships.
- Be willing and able to relocate to the assigned internship location.
- Be eligible to work in the United States without company sponsorship, now or in the future, for employment-based work authorization.
- Assist the team in developing objectives to maintain market share and increase the quality of service to customers.
- Participate in hospital visits and on-site and field training workshops alongside Field Sales Representatives.
- Maintain accurate records of sales expenses, customer files, and required field sales reports.
- Conduct all sales activities according to Travel & Entertainment guidelines and Industry and Integrity Policies.
- Research, develop, and present a project solution at the conclusion of the internship.
Additional Location(s): N/A
Diversity - Innovation - Caring - Global Collaboration - Winning Spirit - High Performance
At Boston Scientific, we’ll give you the opportunity to harness all that’s within you by working in teams of diverse and high-performing employees, tackling some of the most important health industry challenges. With access to the latest tools, information and training, we’ll help you in advancing your skills and career. Here, you’ll be supported in progressing – whatever your ambitions.
About the role:
The purpose of the Medical Device Sales Internship is to introduce students to our exciting and fast-paced Urology Commercial Organization. The goal of the internship is designed to give participants exposure and to obtain an understanding of the diverse functions across the organization including Marketing, R&D, Sales Training and Healthcare Economics.
At Boston Scientific, we value collaboration and synergy. This role follows a field-based work model, requiring employees to work at assigned field locations as needed to meet business and position requirements.
Relocation and housing assistance is not available to those who meet the eligibility criteria.
Boston Scientific will not offer sponsorship or take over sponsorship of an employment VISA for this position at this time
We will consider qualified applicants of all ages who are starting (or restarting) their careers
Your responsibilities will include:
- Assist the team in developing objectives to maintain market share and increase the quality of service to customers.
- Advance our mission of transforming lives through innovative medical solutions that improve the health of patients around the world.
- Participate in hospital visits, on-site and field training workshops alongside Field Sales Representatives.
- Maintain accurate records of sales expenses, customer files and field sales reports required.
- Conduct all sales activities according to Travel & Entertainment (T&E) guidelines, Industry and Integrity Policies.
- Research, develop and present a project solution at conclusion of internship.
- This internship will begin Mid-May and conclude August 2027
Required qualifications:
- Rising Junior or Senior students currently enrolled in an undergraduate degree program in Business / Engineering, or other technical / relevant coursework
- Strong record of academic achievement and leadership experiences
- Demonstrate analytical, technical, communication and problem solving skills
- Able to build and maintain strong customer relationships
- Must be energetic, enthusiastic, determined and goal oriented
- Must be willing and able to relocate to the assigned internship location, as determined by Boston Scientific
- Must be eligible to work in the U.S. without company sponsorship, now or in the future, for employment-based work authorization
Requisition ID: 637304
Hourly Rate: $26/Hour
The anticipated compensation listed above and the value of core and optional employee benefits offered by Boston Scientific (BSC) will vary based on actual location of the position and other pertinent factors considered in determining actual compensation for the role. Compensation will be commensurate with demonstrable level of experience and training, pertinent education including licensure and certifications, among other relevant business or organizational needs. At BSC, it is not typical for an individual to be hired near the bottom or top of the anticipated salary range listed above.
Compensation for non-exempt (hourly), non-sales roles may also include variable compensation from time to time (e.g., any overtime and shift differential) and annual bonus target (subject to plan eligibility and other requirements).
Compensation for exempt, non-sales roles may also include variable compensation, i.e., annual bonus target and long-term incentives (subject to plan eligibility and other requirements.
For MA positions: It is unlawful to require or administer a lie detector test for employment. Violators are subject to criminal penalties and civil liability.
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn.
Boston Scientific maintains a prohibited substance free workplace. Pursuant to Va. Code § 2.2-4312 (2000), Boston Scientific is providing notification that the unlawful manufacture, sale, distribution, dispensation, possession, or use of a controlled substance or marijuana is prohibited in the workplace and that violations will result in disciplinary action up to and including termination.
Please be advised that certain US based positions, including without limitation field sales and service positions that call on hospitals and/or health care centers, require acceptable proof of COVID-19 vaccination status. Candidates will be notified during the interview and selection process if the role(s) for which they have applied require proof of vaccination as a condition of employment. Boston Scientific continues to evaluate its policies and protocols regarding the COVID-19 vaccine and will comply with all applicable state and federal law and healthcare credentialing requirements. As employees of the Company, you will be expected to meet the ongoing requirements for your roles, including any new requirements, should the Company’s policies or protocols change with regard to COVID-19 vaccination.
Among other requirements, Boston Scientific maintains specific prohibited substance testing requirements for safety-sensitive positions. This role is deemed safety-sensitive and, as such, candidates will be subject to a drug test as a pre-employment requirement. The goal of the drug testing is to increase workplace safety in compliance with the applicable law.
About the company
Boston Scientific designs and makes medical devices used in procedures across cardiology, endoscopy, urology, and neuromodulation. Its products help doctors diagnose and treat conditions by guiding minimally invasive interventions and delivering therapies inside the body, with revenue from hospitals and clinics. The firm differentiates itself through a broad, global portfolio and heavy ongoing investment in research and development to expand capabilities and address complex health issues. Its goal is to improve patient care by providing reliable, effective medical devices and solutions that enable clinicians to perform safer, more effective procedures while growing its business.
Company Size
10,001+
Company Stage
IPO
Headquarters
Marlborough, MA
Founded
1979
Get referred to Boston Scientific
See people who can refer or advise you
Simplify's Take
What believers are saying
- September 11, 2026 FDA clearance for SpaceOAR Flex expands prostate cancer workflow offerings.
- Boston Scientific restored remote cardiac monitoring and most operations by September 8, 2026.
- Second-quarter 2026 sales grew 7.5%, showing strong demand before the cyber disruption.
What critics are saying
- August 25, 2026 cyberattack forced Boston Scientific to miss 2026 sales and profit guidance.
- September 25, 2026 FDA Class I recall removed Imager II Angiographic Catheters after tip defects.
- AXIOS and Infinion CX recalls show repeated manufacturing and design-quality failures across franchises.
What makes Boston Scientific unique
- FARAPULSE remains Boston Scientific's category-defining pulsed-field ablation franchise in 2026.
- SpaceOAR Flex extends a differentiated prostate-radiotherapy portfolio with real-time flexible delivery.
- Global scale across cardiology, endoscopy, urology, and neuromodulation diversifies procedure-dependent revenue.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Relocation Assistance
- Performance Bonus
Growth & Insights and Company News
6 month growth
0%1 year growth
12%2 year growth
12%Boston Scientific slashes 2026 guidance third time. By Trisna Anggraini October 29, 2026 Boston Scientific reported a challenging third quarter, marked by a cyberattack and ongoing struggles in key product lines, prompting the company to slash its 2026 earnings and sales guidance for the third consecutive time. The medical device company now projects full-year revenue growth of 4.25%, down from a previous range of 5.5% to 6.5%. Adjusted earnings per share guidance was cut to $3.16 to $3.18 from $3.28 to $3.32, following an earlier February forecast of $3.43 to $3.49. The new guidance, released along with third-quarter results, is a far cry from what was projected at the beginning of the year, when Boston Scientific outlined 2026 sales growth expectations of 10.5% to 11.5%. The third-quarter results included a roughly $150 million revenue hit from a cyberattack that disrupted ordering, manufacturing, and shipping operations. This markedly lower impact compared with the $755 million in revenue losses attributed to a similar cyberattack during the year-ago period, showing the company's ongoing vulnerability to operational disruptions. Overall, Boston Scientific reported $5.14 billion in revenue, representing 1.5% growth compared to the prior year. CEO Mike Mahoney attributed the guidance reductions to persistent challenges in the Watchman and electrophysiology divisions, which historically drove significant growth. Watchman sales fell 6% year-over-year, while electrophysiology declined 5%, contrasting with 30% growth in Watchman sales and triple-digit gains in electrophysiology during 2025. Mahoney highlighted that the slowdown in the left atrial appendage closure market, which includes Watchman, stems from changes in patient identification and referral patterns, while electrophysiology's decline reflects competitive pressures in pulsed field ablation technology. The company also forecast a 3% to 1% sales decline in the fourth quarter and acknowledged that it will be challenged to grow sales and adjusted EPS next year. Boston Scientific's stock dropped nearly 7% to $42.02 following the announcement. The company also delayed its $14.5 billion acquisition of Penumbra, now expecting completion in early 2027 rather than 2026 due to the regulatory process taking a bit of time. "The regulatory process has taken a bit of time," Mahoney said. "We're still very confident in closing the transaction, but based on some of the discussions with the regulatory authorities, we anticipate the early first quarter close."
BSX stock crashes to 4-year lows: Boston Scientific sees Q4 sales declining, CEO remains confident in 'long-term strategy' Published: Oct 28 2026, 09:10 PM IST * FB * TW * Linkdin * Whatsapp * GNFollow Us For full year 2026, Boston Scientific expects reported sales growth of about 4.25%, down from its previous forecast of 5.5% to 6.5%. * The company lowered its full-year adjusted earnings outlook to $3.16 to $3.18 per share, down from $3.28 to $3.32 per share. * Q3 net sales rose 1.5% to $5.14 billion, exceeding Wall Street estimates of $5.04 billion, according to Fiscal.ai * Q4 net sales is expected to decline between 1% and 3% from a year earlier. Shares of Boston Scientific (BSX) tumbled 8% on Wednesday and hit their lowest level since October 2022 earlier in the session after the medical device maker lowered its annual sales outlook and said it expects fourth-quarter revenue to decline. BSX shares are on track for their fifth loss in six sessions. Boston Scientific cuts Q4 sales forecast. Boston Scientific said it expects fourth quarter (Q4) net sales to decline between 1% and 3% from a year earlier. For full year 2026, the company expects reported sales growth of about 4.25%, down from its previous forecast of 5.5% to 6.5%. Organic sales growth is projected at 3.75%, down from an earlier estimate of 5% to 6%. The company also lowered its full-year adjusted earnings outlook to $3.16 to $3.18 per share, down from $3.28 to $3.32 per share. Cybersecurity attack to disrupt FY 2026 financial performance. In August, Boston Scientific disclosed a cybersecurity incident that disrupted manufacturing, order processing, and shipments globally. The company subsequently warned that the disruptions would materially affect its 2026 financial performance, although it expected to recover some lost revenue as operations gradually resumed. On Wednesday, CEO Mike Mahoney acknowledged the difficult year but said he remained "confident in our long-term strategy," citing the company's product portfolio and pipeline of new technologies. Meanwhile, Q3 net sales rose 1.5% to $5.14 billion, exceeding Wall Street estimates of $5.04 billion, according to Fiscal.ai. Adjusted earnings per share slipped to $0.73 from $0.75 last year, but narrowly beat consensus estimates of $0.72 per share. Retail turns bullish on BSX. Despite the slump, retail sentiment surrounding BSX on Stocktwits flipped to 'bullish' from 'bearish' over the past 24 hours, amid 'high' message volumes. The stock has been under strong selling pressure so far this year, crashing more than 56%. Also read: WEN Stock Surges 15% As Trian Fund Offers $1.4B To Take The Burger Chain Private For updates and corrections, email newsroom[at]stocktwits[dot]com.< Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business. 0 Comments / 0 New
Stock market today, Oct. 28: Boston Scientific slips 6% after cutting Q4 sales and full-year EPS guidance on cyberattack impact. Today, Oct. 28, 2026, the medical device maker slashed profit expectations after an August cyberattack continued disrupting operations. BSX - Boston Scientific. $42.43 -$2.63 (-5.84%) NYSE · As of 4:00 PM ET 10/28/26 BSX · 1M -3.81% Key data points. Market cap $65.30B Day's range $39.57 - $43.92 52wk range $39.57 - $105.65 Volume 69.8M Avg volume 19.3M Gross margin 66.36% Boston Scientific (BSX -5.84%), a global medical device maker focused on interventional cardiology and specialty devices, closed at $42.44, down 5.81%. Investors are focused on the cyberattack's lingering disruption and the company's lower fourth-quarter and full-year guidance. Trading volume reached 66.8M shares, coming in about 234% above its three-month average of 20.0M shares. How the markets moved today. S&P 500 (^GSPC +0.28%) closed at 7,744, up 0.28%, while the Nasdaq Composite (^IXIC +0.27%) finished at 26,550, up 0.27%. In the medical devices sector, Medtronic (MDT +0.88%) closed at $94.82, up 0.93%, and Abbott Laboratories (ABT -0.45%) closed at $102.67, down 0.42%, after fresh outlook pressure kept the group in focus. What this means for investors. Boston Scientific guided for 3% to 5% sales growth and $0.80 to $0.82 in adjusted EPS for Q3, and came up shy of both figures today, delivering a 1.5% sales increase and $0.73 in adjusted EPS. Management blamed an eight-day disruption from a cyberattack as the primary culprit, estimating it cost the company 300 basis points in sales growth and $0.07 in adjusted EPS. Making matters worse, the company doesn't believe an immediate turnaround is in sight, guiding for 3.75% sales growth in 2026; rather, a slow rebuilding is more likely over the next year or two. CEO Mahoney explained, "We believe that 2027 will be the trough in the cycle and we have several investments and new innovations coming over the course of the next 3 years." That said, BSX shares now trade at just 13 times forward earnings, so it wouldn't take massive growth to potentially spark such a turnaround - especially considering the company may have upside incoming from its pending acquisition of Penumbra, if it can integrate the deal successfully. I'm keeping an eye on Boston Scientific from a distance, but I'd only want to invest once I start to see signs of progress. Is Boston Scientific a smart long-term play? Before you buy stock in Boston Scientific, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now... and Boston Scientific wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of its recommendation, you'd have $337,166!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of its recommendation, you'd have $1,339,143!* Now, it's worth noting Stock Advisor's total average return is 904% - a market-crushing outperformance compared to 213% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. *Stock Advisor returns as of October 28, 2026.
Boston Scientific said a cyber security incident hurt its third-quarter results, causing a two-week outage with eight business days of manufacturing and shipping disruption. The attack cut sales growth by about 300 basis points and earnings per share by $0.07, and lost revenue came to $150 million. The company expects 2027 to be the low point of its cycle, with recovery in 2028. Weakness in its electrophysiology and WATCHMAN franchises, and pricing pressure in China, weigh on growth. A restructuring programme should save more than $500 million over three years. It also booked an $80 million charge, mostly for product liability cases. The Penumbra acquisition is now expected to close in early 2027 because of regulatory timelines.
Boston Scientific (NYSE:BSX) issues quarterly earnings results. Boston Scientific (NYSE:BSX - Get Free Report) posted its quarterly earnings data on Wednesday. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.01, FiscalAI reports. The business had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.06 billion. Boston Scientific's quarterly revenue was up 1.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.75 EPS. Here are the key takeaways from Boston Scientific's conference call: * Q3 missed expectations: Organic revenue grew 1.5%, below the 3%-5% outlook, while adjusted EPS fell 3% to $0.73. The cybersecurity incident reduced revenue growth by roughly 300 basis points and EPS by approximately $0.07. * Boston Scientific expects continued near-term pressure, guiding to a 1%-3% organic revenue decline and adjusted EPS of $0.77-$0.79 in Q4. Management said 2027 revenue and EPS growth will be challenging as EP and WATCHMAN face market-share and competitive pressures, while China pricing headwinds intensify. * WATCHMAN sales declined 6% and EP sales declined 5% in Q3, with further EP share erosion expected until new products launch. The company also cited weaker urology performance, China-related pricing pressure, supply constraints, and delays affecting parts of its product pipeline. * Management expects a return to stronger performance in 2028, supported by launches including FARAWAVE Ultra, 2D ICE, CRM's Denali platform, new IVL and imaging technologies, and a potential Penumbra contribution. The company identified approximately $25 billion of new market opportunities by 2030. * A company-wide restructuring program is expected to generate more than $500 million in savings over three years, with over half anticipated by the end of 2027. Boston Scientific said the program should improve operating leverage while preserving investment in key growth platforms. Boston Scientific stock down 7.9%. Boston Scientific stock traded down $3.55 during midday trading on Wednesday, reaching $41.51. The company's stock had a trading volume of 22,892,086 shares, compared to its average volume of 18,425,303. Boston Scientific has a fifty-two week low of $39.57 and a fifty-two week high of $105.65. The business has a 50-day simple moving average of $45.29 and a 200-day simple moving average of $57.71. Analyst ratings changes. BSX has been the subject of a number of analyst reports. Stifel Nicolaus reduced their price objective on shares of Boston Scientific from $60.00 to $55.00 and set a "buy" rating for the company in a research note on Monday. Raymond James Financial reissued an "outperform" rating and issued a $57.00 price objective (down from $78.00) on shares of Boston Scientific in a research note on Thursday, July 30th. Evercore cut their price objective on Boston Scientific from $65.00 to $52.00 and set an "outperform" rating on the stock in a research report on Wednesday, October 7th. Piper Sandler reduced their price target on Boston Scientific from $65.00 to $60.00 in a research report on Wednesday, July 29th. Finally, Canaccord Genuity Group lowered their target price on shares of Boston Scientific from $70.00 to $66.00 and set a "buy" rating for the company in a research note on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $65.93. Key headlines impacting Boston Scientific. Here are the key news stories impacting Boston Scientific this week: * Boston Scientific reported third-quarter revenue of $5.138 billion, up 1.5% year over year and ahead of analysts' expectations of approximately $5.06 billion. Adjusted EPS of $0.73 also narrowly exceeded the $0.72 consensus estimate. * The company highlighted operational progress, including enrollment in the Elite AF clinical trial and FDA 510(k) clearances for StoneSmart technologies and an expanded SEISMIQ catheter offering. Cardiovascular sales rose 1.9% on a reported basis, while Latin American sales increased 16%. * Management's results extended Boston Scientific's streak of quarterly earnings beats, but the underlying growth rate remains modest. Revenue increased from $5.065 billion a year earlier, while regional performance was uneven, including a 0.6% decline in Asia-Pacific sales. * Boston Scientific again lowered its fiscal 2026 outlook, now targeting approximately 4.25% reported net-sales growth. Management expects fourth-quarter reported and organic sales to decline 1% to 3%, signaling a difficult finish to the year. * The cybersecurity incident has disrupted business operations and weighed on the company's forecast. Investors appear to be treating the reduced guidance as more important than the quarterly beat, raising concerns about near-term execution and the duration of the incident's financial impact. * Profitability also weakened year over year: GAAP EPS fell to $0.40 from $0.51, while adjusted EPS declined from $0.75 to $0.73. The combination of lower earnings, cybersecurity-related uncertainty and another outlook reduction explains the negative investor reaction. Insider buying and selling. In related news, Director David C. Habiger acquired 2,100 shares of Boston Scientific stock in a transaction on Wednesday, August 5th. The stock was purchased at an average cost of $47.59 per share, with a total value of $99,939.00. Following the purchase, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. The trade was a 13.94% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Edward J. Ludwig purchased 5,000 shares of the business's stock in a transaction dated Friday, July 31st. The shares were bought at an average price of $45.48 per share, with a total value of $227,400.00. Following the purchase, the director directly owned 30,359 shares of the company's stock, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 194,522 shares of company stock worth $9,385,210 in the last ninety days. 0.34% of the stock is owned by corporate insiders. Boston Scientific company profile. Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide. Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation. Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.